Back to results
US 9,289,477 B2Granted
Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
AssigneeSelecta Biosciences, Inc.
InventorsChristopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Life of this patent
Estimating the term…
Abstract
Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.
Claims12
A composition comprising:
- (i) a first population of polymeric synthetic nanocarriers coupled to rapamycin, and
- (ii) a second population of polymeric synthetic nanocarriers coupled to antigens that comprise MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with an undesired CD8+ T cell immune response,
- wherein at least 75% of the polymeric synthetic nanocarriers of the first population of synthetic nanocarriers have a minimum dimension, obtained using dynamic light scattering, that is greater than 110 nm,
- and a maximum dimension, obtained using dynamic light scattering, that is equal to or less than 500 nm,
- wherein the load of the rapamycin on average across the first population of polymeric synthetic nanocarriers is at least 2% but no more than 25% (weight/weight),
- wherein the load of the antigens on average across the second population of polymeric synthetic nanocarriers is between 1% and 10% weight/weight, and
- wherein the composition is in an amount effective to reduce an undesired CD8+ T cell immune response.
4 more elements
Dependencies are inferred from the claim text.